Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.63 |
| ▸ | KDR | P35968 | 13/20 | 0.63 |
| ▸ | CDK1 | P06493 | 12/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874799 | 0.91 | CDK2 (0.64) | CDK2KDRCDK1NPC1MAPT | |
| SCHEMBL13442815 | 0.91 | CDK2 (0.59) | CDK2KDRCDK1NPC1MAPT | |
| SCHEMBL12390722 | 0.86 | KDR (0.65) | CDK2KDRCDK1SYKCA2 | |
| SCHEMBL3934022 | 0.85 | KDR (0.64) | CDK2KDRCDK1CA2CDK9 | |
| SCHEMBL13890223 | 0.80 | CDK1 (0.41) | CDK2KDRCDK1NPC1MAPT | |
| SCHEMBL13874803 | 0.80 | CDK1 (0.56) | CDK2KDRCDK1 | |
| SCHEMBL3934409 | 0.77 | CDK1 (1.00) | CDK2KDRCDK1 | |
| SCHEMBL13944388 | 0.77 | CDK2 (0.78) | CDK2KDRCDK1CA2CDK9 | |
| SCHEMBL13022041 | 0.77 | CDK1 (0.70) | CDK2KDRCDK1 | |
| SCHEMBL2818622 | 0.77 | CDK1 (0.70) | CDK2KDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642611-B2 | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | CDK2 64/4885KDR 1/4885CDK1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.